U.S. markets open in 6 hours 18 minutes

Globus Medical, Inc. (GMED)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
69.20-0.55 (-0.79%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close69.75
Bid0.00 x 900
Ask0.00 x 800
Day's Range68.18 - 69.97
52 Week Range42.85 - 70.00
Avg. Volume464,850
Market Cap6.9B
Beta (5Y Monthly)1.02
PE Ratio (TTM)68.51
EPS (TTM)1.01
Earnings DateMay 05, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est71.47
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-20% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Globus Medical (GMED) Simplifies Spine Surgery With CREO ONE

    Globus Medical (GMED) Simplifies Spine Surgery With CREO ONE

    Globus Medical's (GMED) latest development to robotically navigated spine surgery will enable surgeons to maintain the navigational accuracy without performing traditional pedicle preparation.

  • Globus Medical Announces First Surgeries with Revolutionary CREO ONE™ Robotic Screw

    Globus Medical Announces First Surgeries with Revolutionary CREO ONE™ Robotic Screw

    The Latest Enhancement to Robotically Navigated Spine Surgery with ExcelsiusGPS®AUDUBON, Pa., April 15, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the recent launch of CREO ONE™, the market’s first robotic screw designed for spine surgery with ExcelsiusGPS®. CREO ONE™ enhances the company’s groundbreaking modular pedicle screw platform by simplifying pedicle preparation while maintaining navigational accuracy and increasing pullout strength by 86% compared to traditional pedicle screws tapped to size. The screw is the first of its kind to offer this level of advanced robotic integration, streamlined workflow, and pullout strength. The CREO ONE™ screw’s unique tip may save time and improve efficiency in the OR by reducing procedural steps. “The screw completely eliminates the need to tap and simply requires a starting, pilot hole to break the cortex prior to placing the vertebral pedicle screw, further streamlining the operative workflow while increasing screw pullout strength,” said Dr. Frank La Marca, neurosurgeon in Jackson, Michigan. “The awl-style tip helps the screw follow a pre-planned trajectory and gives me the confidence of maintained navigational accuracy without performing traditional pedicle preparation. This makes the entire procedure easier and more reliable.” CREO ONE™ is part of the CREO AMP® family. CREO ONE™ screws are compatible with CREO MIS® and CREO AMP® screw heads, and use existing CREO® navigation instruments. To learn more, visit GlobusMedical.com/products/CREO-One. About Globus Medical, Inc. Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com. Safe Harbor Statements All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. Contact: Brian Kearns Senior Vice President, Business Development and Investor Relations Phone: (610) 930-1800 Email: investors@globusmedical.com www.globusmedical.com

  • Is GMED Stock A Buy or Sell?
    Insider Monkey

    Is GMED Stock A Buy or Sell?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 887 world-class investment firms that we track and now have access to the collective wisdom contained in […]